SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) FEBRUARY 16, 2005
NORTHWEST BIOTHERAPEUTICS, INC.
| DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION) | 0-33393 (COMMISSION FILE NUMBER) | 94-3306718 (I.R.S. EMPLOYER IDENTIFICATION NO.) |
22322 20th Avenue SE, Suite 150, Bothell, WA 98021
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE (425) 608-3000
INAPPLICABLE
(FORMER NAME OR FORMER ADDRESS IF CHANGED SINCE LAST REPORT)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| ITEM 4.01 Changes in Registrant’s Certifying Accountant. | ||||||||
| SIGNATURE | ||||||||
ITEM 4.01 Changes in Registrant’s Certifying Accountant.
On February 16, 2005, Northwest Biotherapeutics, Inc. (the “Company”) engaged Peterson Sullivan PLLC to act as its new independent auditor. The engagement of Peterson Sullivan PLLC was approved by the Company’s Board of Directors. During the two most recent fiscal years and the interim period up to February 16, 2005, the Company has not consulted with Peterson Sullivan PLLC regarding either:
(i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company nor oral advice was provided that Peterson Sullivan, PLLC concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or
(ii) any matter that was either the subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NORTHWEST BIOTHERAPEUTICS, INC. | ||||
| By: | /s/ Alton L. Boynton | |||
| Alton L. Boynton | ||||
| President | ||||
Dated: February 23, 2005
1